Germany · Delayed Price · Currency is EUR Sol-Gel Technologies Company Description
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally.
The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
| Country | Israel |
| Founded | 1997 |
| Industry | Pharmaceutical Preparations |
| Employees | 34 |
| CEO | Moshe Arkin |
Contact Details
Address: 7 Golda Meir Street Ness Ziona, 7403650 Israel | |
| Phone | 972 8 931 3433 |
| Website | sol-gel.com |
Stock Details
| Ticker Symbol | 4SG |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Moshe Arkin | Chief Executive Officer |
| Eyal Ben-Or | Chief Financial Officer |
| Itzik Yosef | Chief Operating Officer |